Itrapol

Yttrium-90, the active ingredient in Itrapol, is a radiopharmaceutical presented as a radiopharmaceutical for intravascular use. It delivers localized beta radiation to malignant tumors in adult patients. GNH USA supplies Itrapol as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and clinics worldwide.

Itrapol, containing Yttrium-90, is employed in targeted radionuclide therapy for certain cancers. - Unresectable liver cancer: provides internal radiation to hepatic tumors, reducing tumor burden. - Metastatic neuroendocrine tumors: delivers selective beta radiation to metastatic lesions, aiming to control disease progression. - Hepatocellular carcinoma: offers localized radiation to improve local control when surgery is not feasible.

Itrapol may be associated with a range of adverse reactions following administration.

Common Side Effects: - Fatigue: transient tiredness experienced after treatment. - Nausea: mild to moderate upset stomach. - Abdominal pain: discomfort in the upper abdomen. - Fever: low‑grade temperature elevation. - Transient liver enzyme elevation: temporary rise in ALT/AST. - Mild anemia: slight reduction in hemoglobin levels.

Serious or Rare Side Effects: - Radiation‑induced liver disease: severe hepatic dysfunction. - Gastrointestinal ulceration: bleeding or perforation of the GI tract. - Severe thrombocytopenia: markedly low platelet count. - Pulmonary embolism: blockage of pulmonary arteries. - Radiation pneumonitis: inflammation of lung tissue. - Severe infection: opportunistic infections due to immunosuppression.

Prior to using Itrapol, clinicians should observe several safety measures. - Patient selection: evaluate liver function and tumor burden before administration. - Radiation safety: implement shielding and handling protocols for staff. - Pregnancy: avoid use in pregnant patients due to fetal radiation exposure. - Concurrent chemotherapy: assess additive bone‑marrow toxicity. - Monitoring: schedule post‑treatment imaging and laboratory tests. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Itrapol can interact with other therapies that affect radiation dose or blood components.

Major Interactions (Avoid): - Concurrent external beam radiation: may increase cumulative radiation exposure. - High‑dose chemotherapy: can amplify bone‑marrow suppression. - Anticoagulants: may raise bleeding risk after embolization.

Moderate Interactions (Monitor Closely): - Steroids: may modify inflammatory response post‑treatment. - Angiogenesis inhibitors: could alter vascular targeting of microspheres. - Renal‑impairment drugs: monitor renal function as clearance may be affected.